183 related articles for article (PubMed ID: 9822896)
21. Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo.
Goldberg MJ; Ring B; DeSante K; Cerimele B; Hatcher B; Sides G; Wrighton S
J Clin Pharmacol; 1996 Dec; 36(12):1154-60. PubMed ID: 9013373
[TBL] [Abstract][Full Text] [Related]
22. Grapefruit juice activates P-glycoprotein-mediated drug transport.
Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
24. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
25. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Ling SY; Huizinga RB; Mayo PR; Larouche R; Freitag DG; Aspeslet LJ; Foster RT
Br J Clin Pharmacol; 2014 Jun; 77(6):1039-50. PubMed ID: 24330024
[TBL] [Abstract][Full Text] [Related]
27. Erythromycin breath test.
Watkins PB
Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
[No Abstract] [Full Text] [Related]
28. The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs.
KuKanich B; Hubin M
J Vet Pharmacol Ther; 2010 Feb; 33(1):42-9. PubMed ID: 20444024
[TBL] [Abstract][Full Text] [Related]
29. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
30. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
31. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats.
Kanazu T; Okamura N; Yamaguchi Y; Baba T; Koike M
Xenobiotica; 2005 Apr; 35(4):305-17. PubMed ID: 16019953
[TBL] [Abstract][Full Text] [Related]
33. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.
Shah SS; Sasaki K; Hayashi Y; Motoyama S; Helmi AR; Khalil WF; Shimoda M
J Vet Med Sci; 2009 Sep; 71(9):1151-9. PubMed ID: 19801894
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy.
Misaka S; Kurosawa S; Uchida S; Yoshida A; Kato Y; Kagawa Y; Yamada S
J Pharm Pharmacol; 2011 Jan; 63(1):58-64. PubMed ID: 21155816
[TBL] [Abstract][Full Text] [Related]
37. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
Evans DC; O'Connor D; Lake BG; Evers R; Allen C; Hargreaves R
Drug Metab Dispos; 2003 Jul; 31(7):861-9. PubMed ID: 12814962
[TBL] [Abstract][Full Text] [Related]
38. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
39. Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors.
Martínez C; Gervasini G; Agúndez JA; Carrillo JA; Ramos SI; García-Gamito FJ; Gallardo L; Benítez J
Eur J Clin Pharmacol; 2000 May; 56(2):145-51. PubMed ID: 10877009
[TBL] [Abstract][Full Text] [Related]
40. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat.
Li LY; Amidon GL; Kim JS; Heimbach T; Kesisoglou F; Topliss JT; Fleisher D
J Pharmacol Exp Ther; 2002 May; 301(2):586-93. PubMed ID: 11961060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
